glp 1 drug coverage CMS Issues Guidance on GLP-1 Anti-Obesity Drugs The GLP-1 Access Gap: Mapping
Description
Tirzepatides runs until at least 2030
The global respective SURMOUNT study program comprises four randomized controlled trials with a study duration of at least 72 weeks using the tirzepatide doses of 10 and 15 mg in the studies SURMOUNT-2 to SURMOUNT-4 and all three doses, including the 5-mg dose in SURMOUNT-1 (8285)
In the diabetes group, patients on semaglutide had a fourfold increased risk of NAION compared to those on other treatments
However, unchecked chronic inflammation can lead to many different diseases
Merck, Rome, Italy
Accessed December 20, 2019
